Coya Therapeutics, Inc.
COYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -40.8% | – | – | – |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | -233.9% | 8.3% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -483.9% | -122.2% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -418.7% | -133.1% | – | – |
| EPS Diluted | -0.98 | -0.79 | -1.231 | -0.74 |
| % Growth | -24.1% | 35.8% | -66.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |